<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110512</url>
  </required_header>
  <id_info>
    <org_study_id>FLANEO0210</org_study_id>
    <secondary_id>Version 3</secondary_id>
    <nct_id>NCT01110512</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hoped that with the use of medication, occurs improvement of the CVI parameters, such
      as edema, pain, night cramps, functional discomfort, heavy feeling and that the drug test is
      non-inferior than the comparator.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of the parameters of CVI, such as edema of lower members.</measure>
    <time_frame>90 days.</time_frame>
    <description>There will be 06 planned visits (V0, V1, V2, V3, V4 and V5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of the parameters of CVI.</measure>
    <time_frame>90 days</time_frame>
    <description>There will be 06 planned visits (V0, V1, V2, V3, V4 and V5). Assessment of improvement of signs and symptoms secondary to IVC, which are:
paresthesia (tingling);
Itching;
Pain;
cramps at night;
Discomfort functional;
Heaviness.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Venous Insufficiency</condition>
  <arm_group>
    <arm_group_label>Flavonid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Daflon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flavonid</intervention_name>
    <description>Diosmin (450 mg) + hesperidin (50 mg)
1 tablet, 2 times per day.</description>
    <arm_group_label>Flavonid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daflon</intervention_name>
    <description>Diosmin (450 mg) + hesperidin (50 mg)
1 tablet, 2 times per day</description>
    <arm_group_label>Daflon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who agree to the terms described in IC;

          -  Subjects of both genders, aged ≥ 18 and ≤ 75 years with IVC framework of the lower
             limbs;

          -  Subjects with CVI ranked 3 to 5, according to CEAP scale;

          -  Patients complaining of pain and swelling in the lower limbs secondary to IVC;

          -  Subjects with good mental health that can respond adequately to the study
             questionnaires;

          -  Subjects who agree to make any return visits for evaluation;

        Exclusion Criteria:

          -  Patients with CVI classified as 0, 1, 2 or 6, according to CEAP;

          -  Subjects who have received treatment for varicose veins as laser, medication use
             topical or oral (eg: brown India, coumarin, and etc.). And surgery in the 03 months
             preceding the study;

          -  Patients with other diseases that may interfere with the study results: thrombosis,
             coagulation disorders and other diseases that the medical criteria, are important to
             be excluded;

          -  Pregnant or nursing women;

          -  Presence of any medical condition that, according to the investigator, should prevent
             the patient from the study;

          -  Participation in clinical trials in the twelve months preceding the study;

          -  Patients with serious illnesses and uncontrolled that need multidrug treatment;

          -  Patients on diuretics of any kind, regardless of pathology (hypertension, renal or
             liver disease);

          -  Values of laboratory tests appropriate security; the Hemoglobin &lt;10 mg / mL the
             creatinine&gt; 1.5 mg / mL; AST, ALT, GGT ≥ 2 times normal values; the platelet count
             below 90.000/ml; Total Bilirubin and the fractions ≤ 1.5 times the normal range.

          -  past medical history of hypersensitivity to drugs of the same pharmacological classes
             of substances under investigation;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Frederico, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>LAL Clinical Reseach e Development Ltda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Frederico, Psysician</last_name>
    <phone>55 19 3829-3822</phone>
    <email>alexandre@lalclinica.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lal Clínica Pesquisa e Desenvolvimento Ltda</name>
      <address>
        <city>Valinhos</city>
        <state>SP</state>
        <zip>13270000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre Frederico, Psysician</last_name>
      <phone>55 19 3829-3822</phone>
      <email>alexandre@lalclinica.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>April 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2010</study_first_posted>
  <last_update_submitted>October 26, 2010</last_update_submitted>
  <last_update_submitted_qc>October 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Frederico</name_title>
    <organization>LAL Clinica Pesquisa e Desenvolvimento Ltda</organization>
  </responsible_party>
  <keyword>Improvement of CVI parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

